CTOs on the Move

Praxis Precision Medicines

www.praxismedicines.com

 
Praxis is a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system, or CNS, disorders characterized by neuronal imbalance.
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

Praxis Precision Medicines raised $110M on 07/28/2020
Praxis Precision Medicines raised $91.2M on 05/13/2021

Similar Companies

Pharmadule

Pharmadule is a Bedminster, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Atmofizer

The world’s most innovative and effective clean air technology against harmful ultra fine particles incl. COVID-19. Developed in Germany, assembled in the US.

Cwm Environmental Inc

Cwm Environmental Inc is a Kittanning, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Generation Bio

Generation Bio is innovating genetic medicines to provide durable, redosable treatments for people living with rare and prevalent diseases. The company`s non-viral platform incorporates a novel DNA construct called closed-ended DNA, or ceDNA; a unique cell-targeted lipid nanoparticle delivery system, or ctLNP; and a highly scalable capsid-free manufacturing process that uses its proprietary cell-free rapid enzymatic synthesis, or RES, to produce ceDNA. The platform is designed to enable multi-year durability from a single dose, to deliver large genetic payloads, including multiple genes, to specific tissues, and to allow titration and redosing to adjust or extend expression levels in each patient. RES has the potential to expand Generation Bio`s manufacturing scale to hundreds of millions of doses to support their mission to extend the reach of genetic medicine to more people, living with more diseases, around the world.

Inipharm

At Inipharm, we`re building on novel insights and applying our chemistry expertise to develop therapies for patients with liver disease. Inipharm`s lead program is focused on small-molecules to target the activity of HSD17B13, a highly validated, genetically defined target for multiple severe liver and related diseases.